全球新药王落定!礼来明星单品去年卖了2534亿元,背后有中国企业赋能

第一财经
Feb 05

全球年度药王尘埃落定。  2月4日,礼来发布的2025年财报显示,公司的“明星单品”替尔泊肽降糖适应证产品Mounjaro全年销售额达229.65亿美元,同比增长99%,持续抢占全球糖尿病用药市场份额;减重适应证产品Zepbound全年销售额135.42亿美元,同比增长175%。  这两个适应证合计起来,替尔泊肽2025年全年销售额365.07亿美元(折合人民币2534.24亿元),超过诺和诺德司...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10